Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025ACS Applied Materials & InterfacesOpen Access

Self-Assembling Cyclic Peptide Nanotubes for the Delivery of Doxorubicin into Drug-Resistant Cancer Cells

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMarcos Vilela-PicosEGEva González‐FreireFNFederica Novelli

Discussion

Loading...

Member takes

Overview

Synthetic cyclic peptides improve doxorubicin transport in drug-resistant cancer cells, suggesting enhanced treatment options.

Key Points

  • Doxorubicin delivery was enhanced by cyclic peptide nanotubes in drug-resistant cancer cells, showing promise for improved efficacy.
  • Cyclic peptides exhibited amphipathic and cationic properties, facilitating effective interaction with anionic phospholipid-rich membranes.
  • The study utilized synthetic antimicrobial cyclic peptides to develop a combined drug delivery strategy against cellular resistance.
  • Targeting efflux pumps may enhance doxorubicin delivery, indicating new avenues for cancer treatment against resistant forms.

Cite This Study

Vilela-Picos et al. (2025) studied this question.

synapsesocial.com/papers/68bb3d622b87ece8dc956772https://doi.org/10.1021/acsami.5c05264
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Modular design of cyclic peptide – polymer conjugate nanotubes for delivery and tunable release of anti-cancer drug compounds2024 · 8 citations
  2. 2Harnessing the Folding of Antitumor Peptides for Controlled Carrier‐Free Drug Delivery2026
  3. 3Functionalized Fluorescent Nanostructures Generated from Self-Assembly of a Cationic Tripeptide Direct Cell-Selective Chemotherapeutic Drug Delivery2023 · 11 citations
  4. 4Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer2024 · 17 citations
  5. 5Self-Assembled PEGylated Nanocubes Based on Hydrophobic Camptothecin and Doxorubicin for Combinational Therapy of Colorectal Cancer2024 · 4 citations